- Conditions
- COVID19 Behavioral Prophylaxis
- Interventions
- Brief informational infographic, Placebo control (non-behavioral infographic)
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,017 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 1,670
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
- Drug
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
- Conditions
- Weight Loss
- Interventions
- VK2735, Placebo
- Biological
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • Encino, California • Fullerton, California + 44 more
- Conditions
- Obesity
- Interventions
- ARD-101, Placebo
- Drug
- Lead sponsor
- Aardvark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- AZD9056, Etanercept, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Interventions
- Xtressé Hair Growth Gummies, Placebo Comparator
- Other · Dietary Supplement
- Lead sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Maitland, Florida • Port Orange, Florida
- Conditions
- Chemotherapy-related Cognitive Impairment
- Interventions
- Low-Intensity Walking Intervention, Control Group Intervention
- Behavioral
- Lead sponsor
- Ellis Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Schenectady, New York
- Conditions
- Cardiovascular Disease
- Interventions
- bococizumab (PF-04950615), Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 518
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- rivoglitazone HCl, placebo, pioglitazone HCl, pioglitazone HCl 45 mg, metformin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • San Diego, California • San Francisco, California + 14 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Vamikibart, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 36
- States / cities
- Arcadia, California • Poway, California • Sacramento, California + 33 more
- Conditions
- Arthritis Multiple Joint
- Interventions
- Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Glioblastoma
- Interventions
- Not listed
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Cachexia
- Interventions
- Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 11
- States / cities
- Waterbury, Connecticut • Clearwater, Florida • Largo, Florida + 8 more
- Conditions
- Hypertriglyceridemia, Cardiovascular Disease
- Interventions
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 89
- States / cities
- Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more
- Conditions
- Sanfilippo Syndrome, Mucopolysaccharidosis III
- Interventions
- Epidiolex, Placebo
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Chondral Lesion of the Knee, Meniscal Injuries, Cartilage Defects of the Knee, Osteoarthritis (OA) of the Knee
- Interventions
- Bone Marrow Aspirate (BMA), Arthroscopic Debridement Surgery, Saline
- Biological · Procedure · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Post Partum Hemorrhage
- Interventions
- Novel PPH Risk Prediction Model - Comparator Arm B
- Behavioral
- Lead sponsor
- Holly Ende
- Other
- Eligibility
- Female only
- Enrollment
- 12,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes
- Interventions
- Diabetes Strengths Study
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- FLX-787-ODT (orally disintegrating tablet), Placebo ODT
- Drug
- Lead sponsor
- Flex Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Britain, Connecticut + 16 more
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- La Jolla, California • Redlands, California • Santa Maria, California + 44 more
- Conditions
- Hearing Loss
- Interventions
- Low-level Laser Therapy, Placebo Comparator: Disabled Laser
- Radiation · Other
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Infection Secondary to Surgical Procedure
- Interventions
- ALT005 Ophthalmic Prep Solution, saline control, Betadine ophthalmic prep solution
- Drug · Other
- Lead sponsor
- Altacor Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Interventions
- Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more